Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the overlooked penny stocks to invest in. On January 12, Alec Stranahan, an analyst at Bank of America Securities, maintained a Hold rating on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), while setting a price target of $7. In line with the consensus 1-year median price target, the stock boasts an upside potential of 51.84%.
On the same day, Recursion Pharmaceuticals, Inc. disclosed a revised investor presentation ahead of its use at the JP Morgan Healthcare Conference. The presentation highlighted developments in its three core areas: AI-powered drug discovery platform, clinical pipeline, and financial environment. The company outlined its pioneer AI-driven clinical proof-of-concept in familial adenomatous polyposis (REC-4881), offering nearly 15 discovery-stage assets, and milestones with collaborators, including Sanofi, Roche and Genentech.
wavebreakmedia/Shutterstock.com
Additionally, Recursion Pharmaceuticals, Inc. recorded $755 million in unaudited year-end 2025 cash position, anticipating cash runway through the end of 2027. This is backed by risk-adjusted partnership inflows and suggests a 35% decline in pro forma operating expenses from 2024 to 2026, and tighter cost discipline. Overall, management remains committed to positioning the company as a leading AI-native enterprise in the changing drug discovery and development space.
Recursion Pharmaceuticals, Inc. is a Utah-based clinical-stage biotechnology company specializing in the decoding of biology and chemistry. Founded in 2013, the company develops REC-994, REC-2282, and REC-4881, among others.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
